Fibrinolytic Agents

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
DrugDrug NameDrug Indication
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB04932DefibrotideDefibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.
DB05099AncrodFor the treatment of established deep vein thrombosis; central retinal and branch vein thrombosis; priapism; pulmonary hypertension of embolic origin; embolism after insertion of prosthetic cardiac valves; rethrombosis after thrombolytic therapy and rethrombosis after vascular surgery. It is also indicated for the prevention of deep venous thrombosis after repair of the fractured neck of a femur.
DB06271SulodexideSulodexide has been used clinically for the prophylaxis and treatment of vascular diseases with increased risk of thrombosis, including intermittent claudication, peripheral arterial occlusive disease and post-myocardial infarc-tion. Also investigated in the treatment of diabetic kidney disease and diabetic neuropathy. New anti-inflammatory properties have also extended its use in venous disease.
DB06754DanaparoidIndicated for the prophylaxis of post-operative deep venous thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients undergoing elective hip replacement surgery [FDA Label].
DB06779DalteparinDalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
DB06822TinzaparinTinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB13646SaruplaseNot Available
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB00261AnagrelideFor the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
DB00945Acetylsalicylic acidFor use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB05254FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
DB06543AstaxanthinInvestigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00054AbciximabAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
DB00266DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
DB00278ArgatrobanArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
DB01088IloprostUsed for the treatment of pulmonary arterial hypertension.
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB00569FondaparinuxApproved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) treatment of acute DVT and PE; (4) management of UA and NSTEMI for the prevention of death and subsequent myocardial infarction (MI); and (5) management of STEMI for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who are initially to receive no form of reperfusion therapy. Fondaparinux should not be used as the sole anticoagulant during percutaneous coronary intervention (PCI) due to an increased risk of guiding catheter thrombosis.
DB09075EdoxabanEdoxaban is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
DB06294SemuloparinInvestigated for use/treatment in thrombosis.
DrugDrug NameTargetType
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB04932DefibrotideAdenosine receptor A1target
DB04932DefibrotideAdenosine receptor A2atarget
DB04932DefibrotideAdenosine receptor A2btarget
DB05099AncrodFibrinogen alpha chaintarget
DB06271SulodexideHeparin cofactor 2target
DB06271SulodexideAntithrombin-IIItarget
DB06754DanaparoidAntithrombin-IIItarget
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB06779DalteparinHeparanaseenzyme
DB06779DalteparinAntithrombin-IIItarget
DB06779DalteparinP-selectintarget
DB06822TinzaparinAntithrombin-IIItarget
DB06822TinzaparinA disintegrin and metalloproteinase with thrombospondin motifs 4enzyme
DB06822TinzaparinIntegrin alpha-4target
DB06822TinzaparinStromal cell-derived factor 1target
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00261AnagrelidecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00261AnagrelideCytochrome P450 1A2enzyme
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidSerum albumincarrier
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidSolute carrier family 22 member 7transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C8enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidNuclear factor NF-kappa-Btarget
DB04925DesmoteplasePlasminogentarget
DB05254FibrinolysinPlasminogen activator inhibitor 1target
DB05254FibrinolysinUrokinase-type plasminogen activatortarget
DB06543AstaxanthinNF-kappa-B inhibitor alphatarget
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00266DicoumarolVitamin K epoxide reductase complex subunit 1target
DB00266DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DB00266DicoumarolQuinone oxidoreductasetarget
DB00266DicoumarolCytochrome P450 2C9enzyme
DB00266DicoumarolSerum albumincarrier
DB00266DicoumarolCytochrome P450 2C6enzyme
DB00266DicoumarolCytochrome P450 2C11enzyme
DB00278ArgatrobanProthrombintarget
DB00278ArgatrobanCytochrome P450 3A4enzyme
DB00278ArgatrobanCytochrome P450 3A5enzyme
DB01088IloprostProstacyclin receptortarget
DB01088IloprostTissue-type plasminogen activatortarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01088IloprostSolute carrier organic anion transporter family member 2B1transporter
DB01088IloprostSolute carrier organic anion transporter family member 2A1transporter
DB01088IloprostSolute carrier organic anion transporter family member 3A1transporter
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB01088IloprostcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB01088IloprostProstaglandin E2 receptor EP1 subtypetarget
DB01088IloprostProstaglandin D2 receptor 2target
DB00569FondaparinuxAntithrombin-IIItarget
DB00569FondaparinuxCoagulation factor Xtarget
DB09075EdoxabanCoagulation factor Xtarget
DB09075EdoxabanMultidrug resistance protein 1transporter